Related papers: Improved Prediction of Beta-Amyloid and Tau Burden…
Biomarker-assisted diagnosis and intervention in Alzheimer's disease (AD) may be the key to prevention breakthroughs. One of the hallmarks of AD is the accumulation of tau plaques in the human brain. However, current methods to detect tau…
We introduce a framework combining geometric modeling with disease progression analysis to investigate tau deposition in Alzheimer's disease (AD) using positron emission tomography (PET) data. Focusing on the hippocampus, we construct a…
Amyloid-$\beta$ (A$\beta$) plaques in conjunction with hyperphosphorylated tau proteins in the form of neurofibrillary tangles are the two neuropathological hallmarks of Alzheimer's disease. It is well-known that the identification of…
Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by the accumulation of amyloid-beta (A$\beta$) and phosphorylated tau (p-tau) proteins, leading to cognitive decline measured by the Alzheimer's Disease…
Accurate quantification of tau pathology via tau positron emission tomography (PET) scan is crucial for diagnosing and monitoring Alzheimer's disease (AD). However, the high cost and limited availability of tau PET restrict its widespread…
Alzheimer's disease (AD) is a major neurodegenerative condition that affects millions around the world. As one of the main biomarkers in the AD diagnosis procedure, brain amyloid positivity is typically identified by positron emission…
Alzheimer's disease (AD) persists as a paramount challenge in neurological research, characterized by the pathological hallmarks of amyloid-$\beta$ (A$\beta$) plaques and neurofibrillary tangles composed of hyperphosphorylated tau. This…
Background: Alzheimer's Disease (AD) is the most common type of age-related dementia, affecting 6.2 million people aged 65 or older according to CDC data. It is commonly agreed that discovering an effective AD diagnosis biomarker could have…
The formation of amyloid plaques in the cortical and hippocampal brain regions caused by abnormal deposition of extracellular amyloid \b{eta}-protein (A\b{eta}) is a characteristic pathological hallmark of early Alzheimer's disease (AD),…
Alzheimer's disease (AD), defined as an abnormal buildup of amyloid plaques and tau tangles in the brain can be diagnosed with high accuracy based on protein biomarkers via PET or CSF analysis. However, due to the invasive nature of…
Alzheimer's disease is the most common neurodegenerative disorder. Its pathological development is connected with the misfolding and accumulation of two toxic proteins: amyloid-beta and tau proteins. Mathematical models provide a valuable…
Alzheimer's disease (AD) is the most common type of dementia accompanied with brain atrophy. Structural measurements of brain atrophy in specific brain structures such as hippocampus using magnetic resonance imaging (MRI) have been reported…
Motivation: Alzheimer's Disease hallmarks include amyloid-beta deposits and brain atrophy, detectable via PET and MRI scans, respectively. PET is expensive, invasive and exposes patients to ionizing radiation. MRI is cheaper, non-invasive,…
Beta-amyloid positron emission tomography (A$\beta$-PET) imaging has become a critical tool in Alzheimer's disease (AD) research and diagnosis, providing insights into the pathological accumulation of amyloid plaques, one of the hallmarks…
Brain transcriptomics provides insights into the molecular mechanisms by which the brain coordinates its functions and processes. However, existing multimodal methods for predicting Alzheimer's disease (AD) primarily rely on imaging and…
X-ray scattering measurements of in situ human brain tissue encode structural signatures of pathological cross-$\beta$ inclusions, yet systematic exploitation of these data for automated detection remains challenging due to substrate…
Alzheimer disease (AD) is considered one of the leading causes of death in the United States, and there is no effective cure for it. Understanding the neuropathological mechanisms underlying AD is essential for identifying early, reliable…
The prediction of subjects with mild cognitive impairment (MCI) who will progress to Alzheimer's disease (AD) is clinically relevant, and may above all have a significant impact on accelerate the development of new treatments. In this…
Three major biomarkers: beta-amyloid (A), pathologic tau (T), and neurodegeneration (N), are recognized as valid proxies for neuropathologic changes of Alzheimer's disease. While there are extensive studies on cerebrospinal fluids…
Background: Despite the striking efforts in investigating neurobiological factors behind the acquisition of amyloid-\b{eta} (A), protein tau (T), and neurodegeneration ([N]) biomarkers, the mechanistic pathways of how AT[N] biomarkers…